Mr Alazzam is a dual accredited consultant gynaecological surgeon and gynae-oncology subspecialist. His NHS base is Oxford University Hospitals. He is a recognised expert in complex gynaecological surgery both open and minimally invasive; laparoscopy, robotics and hysteroscopic surgery. In addition to oncology, Mr Alazzam is a recognised expert in endometriosis treatment and reconstructive pelvic surgery. He is regularly invited to speak at national and international conferences in the subject. Mr Alazzam is actively involved in research and is widely published. His main areas of interest are health innovation with particular focus on patient-centred care and fertility preservation surgical techniques.
Mr Alazzam’s expertise in diagnostic procedures such as colposcopy and hysteroscopy coupled with his expertise in complex gynaecological surgery allows him to provide comprehensive, high quality care to women presenting with a wide range of gynaecological problems.
Zoe, his PA, is a great asset to his practice. She is kind, passionate, flexible, accommodating and always go over and beyond to make each patient feel special and well looked after.
- Cancer surgery
- Fertility preservation surgery
- Complex laparoscopy & hysteroscopy surgery
- Menstrual problems
- Cosmetic gynaecology
- Pelvic floor surgery
- Ovarian cysts and fibroids
- Enjoying spare time with family
- Sports & keeping fit
Treatments and tests offered by Mr Moiad Alazzam at Nuffield Health
- Adnexal surgery
- Dilation and curettage (D&C)
- Endometrial ablation
- Endometrial resection
- Endometrial Scratch
- Female sterilisation
- Hormonal coil
- Hormone replacement therapy (HRT)
- Hysterectomy surgery
- Hysteroscopic surgery
- Labial reduction (labiaplasty)
- Local anaesthetic
- Ovarian cystectomy
- Pelvic surgery
- PMS clinic
- Vaginal Prolapse Surgery
Tranoulis A, Georgiou D, Alazzam M, Borley J. Combined laparoscopic uterine artery occlusion and myomectomy versus laparoscopic myomectomy: A direct comparison meta-analysis of short and long term outcomes in women with symptomatic leiomyomas. J Minim Invasive Gynecol. 2019 Feb 15. S1553-4650(19) 30090-1.doi:10.1016/j.jmig.2019.02.004[Epub ahead of print]. PMID: 30776497
Lawrie TA, Alazzam M, Tidy J, Hancock BW, Osborne R. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016 Jun 9;(6):CD007102. doi: 10.1002/14651858.CD007102.pub4. Review. PMID: 27281496
ID Gallos, M Alazzam, TJ Clark, R Faraj, AN Rosenthal, PP Smith, JK Gupta. Management of Endometrial Hyperplasia. RCOG Green-top Guideline No.67. February 2016
Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016 Jan 13;1:CD008891. doi: 10.1002/14651858.CD008891.pub3. Review. PMID: 26760424
Jones GL, Jacques RM, Thompson J, Wood HJ, Hughes J, Ledger W, Alazzam M, Radley SC, Tidy JA. The impact of surgery for vulval cancer upon health-related quality of life and pelvic floor outcomes during the first year of treatment: a longitudinal, mixed methods study. Psychooncology. 2015 Sep 25. doi: 10.1002/pon.3992. [Epub ahead of print] PMID: 26403828
Bowes H, Jones G, Thomson J, Alazzam M, Wood H, Hinchliff S, Ledger W, Tidy J. Understanding the impact of the treatment pathway upon health-related quality of life in women with newly diagnosed endometrial cancer – qualitative study. Eur J Oncol Nurs. 2013 Nov 27. [Epub ahead of print]. PMID:24290535.
Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia . Cochrane Database Systematic Review. 2012 Dec 12; 12: CD008891. PMID: 23235667
Alazzam M, Tidy J, Hancock BW, Osborne R, Lawrie TA. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2012 Jul11; 7:CD007102. PMID: 22786502
Alazzam M, Gillespie A, Hewitt M. Robotic surgery in the management of cervical carcinoma. Arch Gynecol Obstet. 2011 Oct ; 284 (4): 937-43. PMID: 21750921
Young T, Coleman R, Hancock B, Drew D, Wilson P, Tidy J. Predicting gestational trophoblastic
neoplasia (GTN): Is urine hCG the answer? Gynecol Oncol. 2011 Sep;
122(3): 595-9. PMID: 21684585
Alazzam M, Tidy J, Hancock BW, Powers HJ. Gestational Trophoblastic Neoplasia, an Ancient Disease: New Light and Potential Therapeutic Targets. Anticancer Agents Med Chem. 2010; 10(2): 176-85. PMID:
Alazzam M, Patterson A, Shafi M. Histologic and colposcopic correlation of cervical cytology showing "? glandular neoplasia". Arch Gynecol Obstet. 2010; 281(4): 703-7. PMID: 19774389.
Alazzam M, Tidy J, Hancock BW, Osborne R. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2009 Jan 21; (1):CD007102. PMID:19160319.
Alazzam M, Hancock BW, Tidy J. Role of Hysterectomy in Managing Persistent Gestational Trophoblastic Disease. J Reprod Med 2008; 53: 519-24.
Book Chapter:Alazzam M and Hancock BW. Gestational trophoblastic disease (GTD); Oxford Desk Reference - Oncology (Eds. T Ajithkumar, N Cook, H Hatcher, A Barrett, M Aapro) ISBN 9780199235636.
- Royal College of Obstetricians & Gynaecologists
- British Society of Gynaecological Endoscopy
- British Society of Colposcopy & Cervical Pathology
- European Society of Gynaecological Oncology
- European Society of Surgical Oncology
- American Association of Laparoscopic Gynaecological Surgeons
Other post held
- Oxford University Hospitals NHS Trust
Insurers Mr Moiad Alazzam works with
Mr Moiad Alazzam works with the following private medical insurance providers:
- Aviva Health
- AXA PPP Healthcare
- AXA PPP International
- Vitality Health (Pru Health)
Mr Moiad Alazzam does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.
Mr Moiad Alazzam does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.
Mr Moiad Alazzam does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.